Sign In
Buy QLGN
$3.21
+0 (+0%)
At Close: Feb 17, 2026
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the L
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
04:20pm, Thursday, 01'st May 2025
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the L
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
09:00am, Friday, 01'st Nov 2024
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued s
Qualigen Therapeutics, Inc. Announces management changes.
05:10pm, Thursday, 26'th Sep 2024
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of director
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
09:00am, Friday, 20'th Sep 2024
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasda
New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
04:30pm, Friday, 06'th Sep 2024
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,05
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
09:00am, Thursday, 05'th Sep 2024
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stoc
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today?
08:19am, Monday, 15'th Jul 2024
Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLG
Why Is Qualigen (QLGN) Stock Up 141% Today?
11:15am, Friday, 12'th Jul 2024
Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior No
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?
08:35am, Monday, 08'th Jul 2024
Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
04:00pm, Thursday, 30'th May 2024
CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (th
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
08:00am, Wednesday, 10'th Apr 2024
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experien
